Clinical Trial Update: A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating an anti-EGFR antibody-drug conjugate in combination with a CDK4/6 inhibitor for recurrent/metastatic head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Anti-EGFR antibody-drug conjugate
• CDK4/6 inhibitor

Snippet

Sponsor: Lei Liu | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING